The VanEck Pharmaceutical ETF has shown strong performance but faces near-term downside risks, prompting a rating downgrade from buy to hold. PPH's valuation has increased significantly, with a high ...
VanEck Pharmaceutical ETF offers focused exposure to large-cap pharmaceutical companies, benefiting from strong long-term demographic and innovation trends. PPH's high concentration in top holdings ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback